Remaining Quantities. Upon Kosan’s request, Licensee shall negotiate in good faith for the transfer to Kosan or its designee all quantities of Reverted Products in the possession of the Licensee.
Remaining Quantities. At the end of the period described in Section 9(e)v.E above, at SGI’s sole election, on a Reverted Product-by-Reverted Product basis and upon SGI’s written request, GSK shall transfer to SGI, at GSK’s Manufacturing Cost plus [***] and the cost of shipping for the Reverted Product, all quantities of reverted Licensed Compounds and Reverted Products in GSK’s possession (including, without limitation, clinical trial supplies and Products intended for commercial sale) that have at least a remaining shelf life of twenty-four (24) months from the date of transfer, in the case of a Territory-wide termination, or in their possession and labeled specifically for sale in any country of the Reverted Territory, in the case of a partial termination. GSK will have no obligation to alter the labeling of such purchased Licensed Compounds and/or Reverted Products for commercialization by SGI.
Remaining Quantities. At the end of the period described in Section 18.7.2, Roche shall transfer to Maxygen, at a price to be agreed in good faith, which shall not be lower than [****] of Roche’s Manufacturing Cost for the Reverted Product or higher than [****] of Roche’s Manufacturing Cost for the Reverted Product, all quantities of reverted Licensed Compounds and Reverted Products in the possession of the Roche Group (including, without limitation, clinical trial supplies and Products intended for commercial sale), in the case of a Territory-wide termination, or in their possession and labeled specifically for sale in any country of the Reverted Territory, in the case of a partial termination. Notwithstanding the above, if as of the effective date of termination Maxygen was sharing Collaboration Costs for the Product that became a Reverted Product, then Roche shall transfer to Maxygen all such quantities of Reverted Product without charge. Roche shall have no obligation to alter the labeling of such purchased Licensed Compounds and/or Reverted Products for commercialization by Maxygen.
Remaining Quantities. Roche shall transfer to Kosan all quantities of reverted Compounds and Reverted Products in the possession of the Roche Group, in the case of a Territory-wide termination, or in their possession and labelled for sale in any country of the Reverted Territory, in the case of a partial termination.
Remaining Quantities. At Roche’s request, Miikana shall sell to Roche ___ * ___quantities of Compound or Derivative related to Reverted Products in the possession of the Miikana Group, in the case of a Territory-wide termination, or in their possession and labeled for sale in any country of the Reverted Territory, in the case of a partial termination, subject to all the disclaimers in Section 9.3. Such sale shall be * at a location identified by Miikana.
